^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
08/29/2023
Excerpt:
Gastric Cancer: Useful in Certain Circumstances…MSI-H/dMMR tumors…Tremelimumab and durvalumab for neoadjuvant therapy only…
Source:
Title:
Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric or gastroesophageal junction cancer with microsatellite instability. Studio con la combinazione di due farmaci immunoterapici come terapia prima della chirurgia o come terapia definitiva in pazienti con tumore gastrico o della giunzione gastro-esofagea operabile con instabilità dei microsatelliti.
Excerpt:
...MSI-high and dMMR status confirmed by IHC and multiplex PCR, and EBV-negative status by ISH, as determined centrally at the Co-ordinating Centre. ...
Trial ID:
Source:
Title:
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
Excerpt:
...(for the phase II section) Have one of the following targeted sequencing results 1) CD274 amplification 2) positive for mutations causing a hypermutation (PMS1, PMS2, MLH1, MLH3, MSH2, MSH3, MSH6, POLD1, POLD2, or POLE) 3) microsatellite instability (MSI high) 4) somatic exonic mutation rate-high 5) EBV positive 9....
Trial ID:
Less C2 evidence
Source:
Title:
INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).
Published date:
01/17/2023
Excerpt:
Overall, 18 pts with MSI/dMMR resectable cT2-4 any N GAC/GEJAC were recruited in Cohort 1….Among 15 evaluable patients, 1 had disease progression and 14 underwent resection. pCR rate was 60% (9/15) and major-complete pathological response (<10% viable cells) was 80%....Pre-operative T300/D for 3 months was safe and provided promising proof of efficacy in MSI, dMMR GAC/GEJAC pts.
DOI:
10.1200/JCO.2023.41.3_suppl.358
Trial ID:
Source:
Title:
Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer.
Published date:
01/17/2023
Excerpt:
Compared to mGC with other genetic alterations (n=25), mGC with TMB >20/Mb or MSI-high mGC (n=23) tended to have a higher ORR (56.5% vs 48%), and a prolonged PFS (median 7.2 vs 4.5 months; 44.0 vs 20.8% at 1 year)….The combination chemotherapy of durvalumab, tremelimumab, and paclitaxel showed encouraging efficacy, especially in mGC with TMB >20/Mb or MSI-high mGC, as a second-line chemotherapy with manageable toxicities in biomarker-selected mGC.
Secondary therapy:
paclitaxel
DOI:
10.1200/JCO.2023.41.3_suppl.401
Trial ID:
